A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.

被引：0
|
作者：
Shapiro, Geoffrey
Supko, Jeffrey G.
Cho, Daniel C.
Hilton, John Frederick
Hadfield, Matthew
Pruitt-Thompson, Salida
Bordoli-Trachsela, Eveline
Zvereva, Nela
Wolanski, Andrew
Sato-DiLorenzo, Aya
Gotthardt, Susan
Fox, Edward A.
Verselis, Sigitas Jonas
Kumar, Ashok
Holden, Sylvia A.
Ram, Siya
Chafai-Fadela, Karima
Harding, Kimberly
Menon, Krishna E.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Massachusetts Gen Hosp, Boston, MA 02114 USA
[3] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[4] KARD Sci, Beverly, MA USA
[5] Cellceutix, Beverly, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2627
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors
    Luke, Jason J.
    Pinato, David J.
    Juric, Dejan
    Lorusso, Patricia
    Hosein, Peter J.
    Desai, Anupam M.
    Haddad, Robert
    de Miguel, Maria
    Cervantes, Andres
    Kim, Won Seog
    Marabelle, Aurelien
    Zhang, Yan
    Rong, Yuanxin
    Yuan, Xiaobin
    Champiat, Stephane
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [22] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 administered daily for 28 days to patients with advanced solid tumors.
    Garrido-Laguna, Ignacio
    Dillon, Patrick Michael
    Anthony, Stephen Patrick
    Janat-Amsbury, Margit
    Ashenbramer, Nissa
    Warner, Steven L.
    Mouritsen, Lars
    Wade, Mark L.
    Whatcott, Clifford
    Bearss, David
    Fu, Siqing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [23] A phase I dose escalation and pharmacodynamic study of AlbuleukinTM administered subcutaneously every other week in patients with advanced solid tumors.
    Syed, SK
    Logan, TF
    Weiss, GR
    Crowder, K
    Rowinsky, E
    Tolcher, A
    Burke, SG
    Grzegorzewski, KJ
    Melder, R
    Fox, RA
    Herpst, JM
    Gallant, G
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6230S - 6230S
  • [24] Phase I/Ib dose-escalation study of aveluma in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022,
  • [25] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Robert, Francisco
    Sandler, Alan
    Schiller, Joan H.
    Liu, Glenn
    Harper, Karen
    Verkh, Lev
    Huang, Xin
    Ilagan, Jennifer
    Tye, Lesley
    Chao, Richard
    Traynor, Anne M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 669 - 680
  • [26] Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
    Francisco Robert
    Alan Sandler
    Joan H. Schiller
    Glenn Liu
    Karen Harper
    Lev Verkh
    Xin Huang
    Jennifer Ilagan
    Lesley Tye
    Richard Chao
    Anne M. Traynor
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 669 - 680
  • [27] A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors
    Gordon, Michael S.
    Springett, Gregory M.
    Su, Yungpo Bernard
    Ould-Kaci, Mahmoud
    Wind, Sven
    Zhao, Yihua
    LoRusso, Patricia M.
    FUTURE ONCOLOGY, 2015, 11 (10) : 1479 - 1491
  • [28] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [29] Phase I/Ib dose-escalation study of avelumab in Chinese patients with advanced solid tumors
    Wu, Yi-Long
    Cheng, Ying
    Chen, Huajun
    Tu, Haiyan
    Xu, Chongrui
    Wang, Zhen
    Liu, Ying
    Xin, Ying
    Lou, Haizhou
    Wang, Wei
    Chin, Kevin
    Li, Dandan
    Zhao, Di
    Gao, Yanfei
    Xu, Wenping
    Pan, Hongming
    FUTURE ONCOLOGY, 2022, 18 (17) : 2053 - 2062
  • [30] Phase I dose-escalation study of IBI351 (GFH925) monotherapy in patients with advanced solid tumors.
    Zhou, Qing
    Yang, Nong
    Zhao, Jun
    Dong, Xiaorong
    Wang, Huijuan
    Yuan, Ying
    Yu, Yan
    Zhang, Meijiang
    Zhang, Sujie
    Huang, Mengna
    Shen, Yuping
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345